Canagliflozin CAS 842133-18-0 purity 99% with Preferential price

Canagliflozin More Information

Canagliflozin is an oral medication that belongs to the class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. It is primarily used for the management of type 2 diabetes mellitus. By inhibiting the SGLT2 protein in the kidneys, canagliflozin reduces the reabsorption of glucose, leading to increased glucose excretion in the urine and consequently lowering blood glucose levels.

The mechanism of action involves the prevention of glucose reabsorption in the proximal convoluted tubule of the nephron, which results in lower plasma glucose levels. This effects not only contribute to glycemic control but may also assist in weight loss and lowering blood pressure, making it a beneficial option for many patients with type 2 diabetes, especially those who are overweight or have hypertension.

Canagliflozin is typically prescribed in conjunction with diet and exercise to improve glycemic control. It can be used alone or in combination with other antidiabetic agents, including metformin, sulfonylureas, or insulin, depending on the individual patient’s needs.

Common side effects associated with canagliflozin include urinary tract infections, genital mycotic infections, increased urination, and dehydration. Patients may also experience side effects such as dizziness, hypotension, and acute kidney injury. Due to its mechanism of action, there is also an increased risk of diabetic ketoacidosis, which is a serious condition that must be monitored for in patients.

It is important for healthcare providers to assess a patient's renal function before initiating treatment with canagliflozin, as the drug is contraindicated in patients with severe renal impairment or end-stage renal disease. Additionally, the use of canagliflozin in pregnant or breastfeeding women should be approached with caution, as there is insufficient data on its safety in these populations.

In recent studies, canagliflozin has also shown cardiovascular benefits. Clinical trials have indicated that it may reduce the risk of cardiovascular events in patients with established cardiovascular disease or at high risk. This highlights its dual role in managing not only blood glucose levels but also long-term cardiovascular health.

In summary, canagliflozin is an SGLT2 inhibitor used to manage type 2 diabetes mellitus by promoting glucose excretion through the urine. It offers additional benefits such as weight loss and potential cardiovascular protection, but its use requires careful consideration of renal function and monitoring for side effects. A comprehensive evaluation by a healthcare provider is essential to ensure its appropriateness for individual patients.